Dublin, May 29, 2025 (GLOBE NEWSWIRE) -- The "Turkey Pharmaceuticals Market, By Region, Competition, Forecast & Opportunities, 2020-2030F" has been added to ResearchAndMarkets.com's offering.
The Turkey Pharmaceuticals Market was valued at USD 2.10 Billion in 2024, and is expected to reach USD 2.70 Billion by 2030, rising at a CAGR of 4.25%
The market has shown steady growth driven by rising healthcare expenditure, demographic shifts, and evolving health policy frameworks. As one of the leading pharmaceutical markets in the MENA region, Turkey plays a key role in the global pharmaceutical landscape. The presence of multinational corporations in specialized areas such as oncology, immunology, and rare diseases has strengthened the high-value segment.
Concurrently, domestic manufacturers have expanded their capabilities in generic drugs, biosimilars, and API production, increasing competitiveness and improving market access. While this enhances local capacity and self-sufficiency, it also presents challenges related to pricing and regulatory complexities.
Key Market Drivers: Growing Healthcare Needs and Aging Population:
The rising healthcare demands coupled with Turkey's aging population are central to the market's expansion. Healthcare spending accounts for around 4.5% of the country's GDP, with per capita expenditure increasing significantly since the implementation of the Healthcare Transformation Program in 2002.
According to OECD data, spending per capita has reached USD 857, reflecting a continued investment in improving healthcare access and quality. An aging population is leading to a growing prevalence of non-communicable diseases such as cancer, diabetes, cardiovascular conditions, arthritis, and Alzheimer's. This epidemiological transition is increasing the need for long-term treatments and pharmaceuticals, significantly influencing drug consumption trends and creating long-term opportunities for the industry.
Key Market Challenges: Pricing and Reimbursement Constraints
A major constraint in the Turkish pharmaceutical market is the government's strict pricing and reimbursement mechanisms aimed at cost containment. The use of an international reference pricing system: based on the lowest drug prices in selected European countries: often results in suppressed pricing levels.
Additionally, the long-standing artificial exchange rate applied to pharmaceutical imports further reduces the profitability of international companies operating in Turkey. These pricing models, coupled with prolonged reimbursement approval timelines, limit the financial viability of launching new and innovative drugs. Such policies have the potential to deter foreign investment, limit product variety, and reduce patient access to cutting-edge therapies, ultimately affecting market innovation and growth.
Key Market Trends: Digitalization of Healthcare and E-Pharmacy Expansion
The Turkish pharmaceutical industry is increasingly embracing digital transformation through the adoption of telemedicine, electronic prescriptions, health informatics, and online pharmacies. These developments are streamlining healthcare delivery, improving compliance, and opening up new revenue opportunities.
The integration of e-prescription systems has enhanced drug traceability and inventory oversight for pharmacies. With the rising popularity of online purchasing: especially among urban consumers: pharmaceutical firms are expanding their e-commerce capabilities. Additionally, the normalization of digital consultations and remote healthcare services post-pandemic has led to an uptick in outpatient pharmaceutical sales, signaling a fundamental shift in how medicines are accessed and consumed.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 85 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value (USD) in 2024 | $2.1 Billion |
| Forecasted Market Value (USD) by 2030 | $2.7 Billion |
| Compound Annual Growth Rate | 4.2% |
| Regions Covered | Turkey |
Report Scope
Key Market Players:
- Amgen Inc.
- Bilim Ilac Sanayii ve Ticaret Anonim Sirketi
- Bristol-Myers Squibb Company
- EastPharma Ltd
- Ferring Ilac Sanayi ve Ticaret Ltd Sti (Ferring Global)
- Gensenta Ilac Sanayi ve Ticaret A.S.
- GlaxoSmithKline Turkey
- ITALFARMACO S.p.A.
- Menarini Turkiye (Menarini Group)
- Merck & Co.
- MS Pharma
- Novartis Turkey
- Pfizer Turkey
- Takeda Pharmaceutical Company
Turkey Pharmaceuticals Market, By Drug Type:
- Generic
- Branded Drugs
Turkey Pharmaceuticals Market, By Product Type:
- Over-The-Counter Drugs
- Prescription Drugs
Turkey Pharmaceuticals Market, By Application:
- Cardiovascular
- Oncology
- Metabolic Disorder
- Musculoskeletal
- Anti-infective
- Others
Turkey Pharmaceuticals Market, By Distribution Channel:
- Retail Pharmacy
- Hospital Pharmacy
- E-Pharmacy
Turkey Pharmaceuticals Market, By Region:
- Marmara Region
- Central Anatolia
- Eastern Anatolia Region
- South-Eastern Anatolia Region
- Aegean Region
- Mediterranean Region
- Black Sea Region
For more information about this report visit https://www.researchandmarkets.com/r/kuc4yv
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
